Comparative Pharmacology
Head-to-head clinical analysis: GONAL F versus METRODIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F versus METRODIN.
GONAL-F vs METRODIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates pituitary gonadotropin release, then downregulates GnRH receptors, suppressing LH and FSH secretion.
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
Terminal elimination half-life is approximately 35 hours (range 28–48 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Primarily renal, with approximately 75% of a dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for less than 5% of elimination.
Category C
Category C
Gonadotropin
Gonadotropin